230 related articles for article (PubMed ID: 21595295)
21. An attack of acute neuro-Behçet's disease during the course of chronic progressive neuro-Behçet's disease: report of two cases.
Matsui T; Ishida T; Tono T; Yoshida T; Sato S; Hirohata S
Mod Rheumatol; 2010 Dec; 20(6):621-6. PubMed ID: 20617356
[TBL] [Abstract][Full Text] [Related]
22. Botulinum toxin-induced acute anterior uveitis in a patient with Behçet's disease under infliximab treatment: a case report.
Sasajima H; Yagi S; Osada H; Zako M
J Med Case Rep; 2017 May; 11(1):124. PubMed ID: 28468639
[TBL] [Abstract][Full Text] [Related]
23. [Efficacy and safety of anti-tumor necrosis factor α monoclonal antibodies in 16 patients with severe/refractory vasculo Behcet's disease].
Li L; Liu JJ; Yu X; Wu D; Zhang SZ; Yang YJ; Zhou JX; Zeng XF; Zhang FC; Zheng WJ
Zhonghua Nei Ke Za Zhi; 2020 Apr; 59(4):303-308. PubMed ID: 32209197
[No Abstract] [Full Text] [Related]
24. Behçet's disease; A rare refractory patient with vena cava superior syndrome treated with infliximab: a case report and review of the literature.
Uyaroglu OA; Erden A; Kilic L; Peynircioğlu B; Karadag O; Kalyoncu U
Acta Clin Belg; 2019 Oct; 74(5):364-369. PubMed ID: 30220250
[No Abstract] [Full Text] [Related]
25. Resolution of Behçet's syndrome associated pulmonary arterial aneurysms with infliximab.
Schreiber BE; Noor N; Juli CF; Haskard DO
Semin Arthritis Rheum; 2011 Dec; 41(3):482-7. PubMed ID: 21546064
[TBL] [Abstract][Full Text] [Related]
26. Real-world efficacy of adalimumab and infliximab for refractory intestinal Behçet's disease.
Sugimura N; Mizoshita T; Sugiyama T; Togawa S; Miyaki T; Suzuki T; Tanida S; Kataoka H; Sasaki M
Dig Liver Dis; 2019 Jul; 51(7):967-971. PubMed ID: 30872086
[TBL] [Abstract][Full Text] [Related]
27. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis.
Ohno S; Nakamura S; Hori S; Shimakawa M; Kawashima H; Mochizuki M; Sugita S; Ueno S; Yoshizaki K; Inaba G
J Rheumatol; 2004 Jul; 31(7):1362-8. PubMed ID: 15229958
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of infliximab on the acute attack of uveitis.
Alokaily F; Alsaleh S; Al-Balawi M; Al-Rashidi S
Saudi Med J; 2010 Jan; 31(1):82-5. PubMed ID: 20062906
[TBL] [Abstract][Full Text] [Related]
29. Infliximab for reversible dementia in acute onset of neuro-Behçet's disease: A case report and cytokine analysis.
Imabayashi K; Ayano M; Higashioka K; Yokoyama K; Yamamoto K; Takayama K; Mitoma H; Kimoto Y; Akahoshi M; Arinobu Y; Akashi K; Horiuchi T; Niiro H
J Neuroimmunol; 2021 Aug; 357():577631. PubMed ID: 34153801
[TBL] [Abstract][Full Text] [Related]
30. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
[TBL] [Abstract][Full Text] [Related]
31. [Infliximab treatment for Behçet's disease--beginning of the biological drug era].
Namba K
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):85-6. PubMed ID: 20187504
[No Abstract] [Full Text] [Related]
32. [A case of neuro-Behçet's disease triggered by herpes zoster-associated uveitis].
Okamoto N; Ogawa N; Kitamura A; Yamakawa I; Kim H; Urushitani M
Rinsho Shinkeigaku; 2021 Sep; 61(9):640-645. PubMed ID: 34433748
[TBL] [Abstract][Full Text] [Related]
33. Improvement of neurological and ocular symptoms of Behçet's disease after the introduction of infliximab.
Barešić M; Reihl M; Habek M; Vukojević N; Anić B
Rheumatol Int; 2018 Jul; 38(7):1301-1306. PubMed ID: 29777341
[TBL] [Abstract][Full Text] [Related]
34. [Granulomatous interstitial nephritis in a patient with Behçet's disease treated with infliximab].
Yoshioka T; Yamakawa T; Yamaguchi M; Nomura R
Nihon Jinzo Gakkai Shi; 2013; 55(8):1412-7. PubMed ID: 24568038
[TBL] [Abstract][Full Text] [Related]
35. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
36. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and safety of infliximab in the treatment of Behçet's disease.
Capella MJ; Foster CS
Ocul Immunol Inflamm; 2012 Jun; 20(3):198-202. PubMed ID: 22486265
[TBL] [Abstract][Full Text] [Related]
38. Multi-drug resistance and side-effects in a patient with Behçet's disease.
Accorinti M; Pesci FR; Pirraglia MP; Priori R; Pivetti-Pezzi P
Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S141-4. PubMed ID: 25962416
[TBL] [Abstract][Full Text] [Related]
39. Neurological Sequelae in Youngest Adult Behcet's Disease Patient on Infliximab.
Sultan M; Khan A; Habib SS; Hayat M
J Coll Physicians Surg Pak; 2020 Jul; 30(7):762-764. PubMed ID: 32811612
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Behçet's disease: a large-scale, long-term postmarketing surveillance in Japan.
Ohno S; Umebayashi I; Matsukawa M; Goto T; Yano T
Arthritis Res Ther; 2019 Jan; 21(1):2. PubMed ID: 30611312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
